

Anthocyanins and Cardiovascular Disease Mechanisms Benefits and Interventions

Kexin Jiang

Food Quality and Safety, Shanghai Business School, Shanghai, 200235, China

ABSTRACT

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, driving increasing interest in dietary strategies that may reduce its burden. Anthocyanins, a subclass of flavonoids abundant in berries, purple cabbage, cherries, and other plant-based foods, have attracted significant attention due to their antioxidant, anti-inflammatory, and metabolic regulatory properties. This review synthesizes current evidence on the sources, chemical characteristics, mechanisms of action, and health effects of anthocyanins in the context of CVD prevention and management. Data from biochemical, molecular, animal, and human studies indicate that anthocyanins can modulate oxidative stress, lipid metabolism, endothelial function, insulin sensitivity, and inflammatory pathways. These effects are mediated through antioxidant enzyme activation, inhibition of lipid peroxidation, modulation of vascular endothelial growth factor (VEGF) expression, and regulation of gene and microRNA activity involved in vascular homeostasis. The review also highlights the impact of anthocyanins on key cardiovascular biomarkers, including LDL and HDL cholesterol and inflammatory cytokines, as well as emerging evidence on novel formulations designed to enhance stability and bioavailability. While findings strongly support the potential cardiovascular benefits of anthocyanin-rich diets, limitations such as variability in study designs, inconsistent dosages, low bioavailability, and limited long-term data hinder definitive conclusions. Future research should focus on standardized, large-scale, longitudinal clinical trials, advanced metabolomic approaches, and innovative delivery systems to improve efficacy and translational relevance. Overall, anthocyanins represent a promising, naturally occurring class of compounds with considerable potential as part of evidence-based dietary interventions for cardiovascular health promotion.

KEYWORDS

Anthocyanins; Cardiovascular disease; Antioxidant activity; Anti-inflammatory mechanisms; Lipid metabolism; Endothelial function; Bioavailability; Dietary intervention

1 Introduction

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, prompting extensive research into dietary interventions that may mitigate its risks. Among the various bioactive compounds under investigation, anthocyanins have emerged as a subject of significant interest due to their potential role in promoting cardiovascular health^[1-2]. These natural pigments, found abundantly in fruits and vegetables, exhibit promising properties that may influence CVD risk factors, though the mechanisms underlying their effects remain incompletely understood^[3]. While some studies suggest an association between habitual anthocyanin intake and reduced risk of nonfatal myocardial infarction and ischemic stroke in men, the need for mechanistic insights and clinical validation persists^[2]. Additionally, there is ongoing debate regarding the stability of anthocyanins and their metabolic fate, which complicates definitive conclusions about their impact on chronic diseases^[4]. The current body of literature highlights the importance of well-designed experimental and human studies to elucidate how these compounds affect vascular function and overall cardiovascular health^[5]. In this context, understanding both the therapeutic potential and limitations of anthocyanins is crucial for establishing evidence-based dietary recommendations aimed at improving public health outcomes^[6].

2 Sources and chemical properties of anthocyanins

Anthocyanins, a class of flavonoids widely distributed in nature, have gained substantial attention due to their potential health benefits, particularly in cardiovascular disease prevention. This chapter explores the diverse natural sources of anthocyanins, such as berries, purple cabbage, and cherries, alongside an in-depth analysis of their chemical structure and characteristics. These properties are integral to understanding their biological activities and subsequent therapeutic applications across various systems^[7]. The comprehensive overview provided here sets the foundation for further exploration of their impact on cardiovascular health.

2.1 Natural sources of anthocyanins

Anthocyanins are predominantly found in a variety of fruits, vegetables, and other plant-based foods, with berries being one of the most prominent sources. Berries such as blueberries, blackberries, and strawberries are rich in anthocyanins and have been extensively studied for their role in promoting cardiovascular health^[8]. These compounds

contribute to the vibrant colors of these fruits while also offering significant antioxidant and anti-inflammatory properties. In addition to berries, purple cabbage has emerged as another potent source of anthocyanins, as highlighted by recent work demonstrating its formulation into nutraceutical products that maintain cardiovascular function ^[9]. Cherries, too, have been identified as a valuable dietary source, with current research summarizing their effects on chronic disease management and cardiovascular risk reduction through clinical trials and in vivo studies ^[10]. Furthermore, dietary intake assessments among Chinese populations reinforce the importance of anthocyanin-rich foods in daily nutrition, emphasizing their preventive benefits against cardiovascular diseases ^[11]. Collectively, these findings underscore the diversity and accessibility of natural anthocyanin sources, making them highly relevant for public health recommendations.

2.2 Chemical structure and characteristics of anthocyanins

The chemical structure of anthocyanins is central to their biological activity and functional roles within the body. Structurally, anthocyanins belong to the flavonoid family and consist of an aglycone core (anthocyanidin) bound to sugar moieties, which influences their stability and bioavailability ^[7]. Variations in glycosylation patterns and acylation can significantly alter their physicochemical properties, including solubility, absorption rates, and interactions with cellular targets. For instance, structural differences partially explain variations in bioactivity observed across different food matrices. Additionally, studies have elucidated how specific anthocyanins modulate endothelial nitric oxide synthase activity, thereby contributing to improved vascular function ^[8]. The pharmacokinetics and bioavailability of these compounds remain critical areas of investigation, as highlighted by gaps in understanding their metabolism and systemic distribution ^[7]. However, challenges persist in correlating laboratory findings with human physiological responses due to limitations in analytical methods and inter-individual variability in metabolism. These complexities necessitate further exploration to fully comprehend the mechanisms underlying their vascular protective actions ^[12].

2.3 Emerging evidence on anthocyanin formulations

Beyond traditional dietary consumption, innovative formulations incorporating anthocyanins are gaining traction in cardiovascular health maintenance. Research has demonstrated the feasibility of developing processed products like "Ceamond Crispy," derived from purple cabbage, which retains anthocyanin content while enhancing consumer appeal ^[9]. Such advancements highlight the potential synergy between natural compounds and modern food technology. Similarly, studies evaluating combinations of anthocyanins with other bioactive compounds, such as iridoids, indicate synergistic effects on liver and cardiovascular parameters ^[13]. These findings suggest that targeted formulations could optimize anthocyanin delivery and efficacy, paving the way for novel nutritional interventions. Nonetheless, experimental data remains limited, particularly regarding long-term safety and effectiveness under varied dietary contexts ^[14]. Thus, while promising, further validation through rigorous clinical trials is essential to establish robust evidence supporting these emerging applications.

3 Mechanisms of action of anthocyanins on cardiovascular disease

Anthocyanins, a class of flavonoids widely distributed in nature, have garnered significant attention for their potential protective effects against cardiovascular disease (CVD). These bioactive compounds exert their therapeutic effects through multiple molecular and cellular mechanisms, including antioxidant, anti-angiogenic, and anti-inflammatory pathways. This chapter explores the evidence from recent studies to elucidate how anthocyanins modulate these mechanisms and contribute to cardiovascular health. Insights drawn from biochemical, animal, and clinical studies provide a comprehensive understanding of their modes of action ^{[15][16][17]}.

3.1 Antioxidant mechanisms

The antioxidant properties of anthocyanins are among the most well-documented mechanisms underlying their cardiovascular benefits. By scavenging reactive oxygen species (ROS) and reducing oxidative stress, anthocyanins protect vascular endothelial cells from damage induced by free radicals. Krga and Milenkovic (2019) ^[15] highlight that anthocyanins enhance the activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, thereby maintaining redox balance within the cardiovascular system. Additionally, these compounds inhibit lipid peroxidation, which is critical for preventing the development of atherosclerosis. Zhao et al. (2024) ^[18] further elaborate that anthocyanins improve vascular function by mitigating oxidative modifications of low-density lipoprotein (LDL), a key contributor to plaque formation. Evidence also suggests that anthocyanins interact with cell-signaling pathways,

including those mediated by nuclear factor erythroid 2-related factor 2 (Nrf2), to upregulate antioxidant gene expression^[15]. Despite these advances, limitations remain, particularly regarding the bioavailability of anthocyanins and their metabolites, which may vary depending on dietary sources and individual physiological factors.

3.2 Anti-angiogenic and anti-inflammatory mechanisms

In addition to their antioxidant capacity, anthocyanins exhibit potent anti-angiogenic and anti-inflammatory effects, which play crucial roles in CVD prevention. Bagchi et al. (2004)^[19] describe the anti-angiogenic properties of anthocyanin-rich extracts, demonstrating their ability to suppress aberrant blood vessel formation, a process implicated in the progression of atherosclerosis and other vascular disorders. Anthocyanins achieve this by modulating the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF). Furthermore, their anti-inflammatory actions involve the inhibition of pro-inflammatory cytokines and chemokines, thereby reducing chronic inflammation—a major driver of cardiovascular pathology^[17]. The review by de Pascual-Teresa et al. (2010)^[16] underscores the importance of these mechanisms in attenuating endothelial dysfunction and improving overall vascular health. Notably, Amini (2017)^[20] reports that anthocyanins can counteract the deleterious effects of high-fat diets by modulating immune responses and reducing systemic inflammation. While these findings are promising, inconsistencies in study designs and dosing regimens across preclinical and clinical investigations necessitate further research to optimize therapeutic applications. Moreover, interactions between anthocyanins and microRNAs (miRNAs) are increasingly recognized as a novel regulatory mechanism influencing inflammatory pathways, though this area requires more in-depth exploration^[15].

3.3 Modulation of gene and protein expression

Recent advancements in molecular biology have shed light on how anthocyanins influence gene and protein expression to confer cardiovascular protection. According to Krga and Milenkovic (2019)^[15], anthocyanins regulate the expression of genes involved in oxidative stress response, inflammation, and lipid metabolism, often through epigenetic modifications. For instance, they modulate histone acetylation and DNA methylation patterns, which can alter the transcriptional activity of target genes. Furthermore, anthocyanins interact with specific miRNAs, small non-coding RNA molecules that post-transcriptionally regulate gene expression, to fine-tune cellular responses to pathological stimuli^[15]. These insights are complemented by Zhao et al. (2024)^[18], who emphasize the role of anthocyanins in improving endothelial nitric oxide synthase (eNOS) expression, a key enzyme responsible for vasodilation and vascular homeostasis. However, while these molecular mechanisms are well-supported in vitro, their translation to human physiology remains imperfectly understood, highlighting the need for longitudinal clinical trials to validate these findings.

4 Impact of anthocyanins on cardiovascular health - related biomarkers

Anthocyanins, a subclass of flavonoids abundant in various fruits and vegetables, have garnered significant attention for their potential to modulate cardiovascular health-related biomarkers. This chapter examines the impact of anthocyanins on key biomarkers such as cholesterol levels and insulin sensitivity, supported by evidence from recent studies. The findings underscore the potential mechanisms through which anthocyanins exert their effects, while also highlighting areas requiring further investigation^{[21][22][23][24][25][26][27]}.

4.1 Effects on cholesterol levels

The modulation of cholesterol levels is one of the most extensively studied effects of anthocyanins on cardiovascular health. Research indicates that anthocyanin supplementation can significantly improve serum concentrations of LDL- and HDL-cholesterol, two critical biomarkers associated with cardiovascular risk. For instance, Yuanyuan Qin et al. (2009) demonstrated that anthocyanin intake inhibits cholesteryl ester transfer protein (CETP), thereby enhancing cellular cholesterol efflux to serum, which results in improved lipid profiles^[22]. Supporting this, T. Wallace et al. (2016) conducted a systematic review of randomized controlled trials (RCTs) and concluded that anthocyanin supplementation may decrease LDL cholesterol among individuals with elevated biomarkers, showcasing the potential therapeutic utility of anthocyanins^[21]. Furthermore, studies by Xueying Yang et al. (2013) and Bei'an You and Haiqing Gao (2003) highlight the role of anthocyanins in regulating lipid metabolism and reducing cholesterol levels, contributing to their anti-atherosclerotic effects^{[25][26]}. These findings collectively suggest that anthocyanins influence cholesterol homeostasis, although differences in study populations, dosages, and durations warrant cautious interpretation of the results^[27].

4.2 Effects on insulin sensitivity and hyperglycemia

In addition to their lipid-modulating properties, anthocyanins have been shown to ameliorate hyperglycemia and enhance insulin sensitivity, both of which are integral to cardiovascular health. Masahito Takikawa et al. (2010) reported that dietary bilberry extract rich in anthocyanins activates AMP-activated protein kinase (AMPK) in diabetic mice, leading to improved glucose metabolism and insulin sensitivity^[23]. This biochemical mechanism aligns with findings from Nima Mohammadi et al. (2024), who systematically reviewed interventions involving anthocyanin-containing foods and nutraceuticals, concluding that regular consumption improves glycemic control and mitigates inflammation^[27]. Qijie Qin (2021) further emphasized the multifaceted role of anthocyanins in protecting against vascular dysfunction and reducing oxidative stress, which indirectly supports insulin signaling pathways^[24]. While these studies provide robust evidence for the beneficial effects of anthocyanins on insulin sensitivity, variations in experimental designs and heterogeneous study populations suggest the need for standardized protocols in future investigations^[21].

4.3 Antioxidant and anti-inflammatory contributions

Beyond direct effects on cholesterol and insulin sensitivity, anthocyanins exhibit potent antioxidant and anti-inflammatory properties that contribute to their cardiovascular benefits. As discussed by Xueying Yang et al. (2013) and Qijie Qin (2021), anthocyanins function as powerful free radical scavengers, reducing oxidative stress and inflammation, which are key drivers of cardiovascular disease progression^{[24][25]}. Nima Mohammadi et al. (2024) corroborated these findings, emphasizing the role of anthocyanins in improving vascular function and modulating lipid profiles through their antioxidant capabilities^[27]. These protective mechanisms not only reinforce the importance of anthocyanins in cardiovascular health but also highlight their potential as therapeutic agents in preventing chronic diseases linked to oxidative stress^[26]. However, the precise molecular pathways underlying these effects remain an area for further exploration.

5 Evidence from animal and human studies

This chapter evaluates the scientific evidence regarding the effects of anthocyanins on cardiovascular disease, drawing from both animal and human studies. These investigations provide critical insights into the mechanisms by which anthocyanins exert their beneficial effects on cardiovascular health, as well as the translational relevance of preclinical findings to human populations^[11]. By synthesizing data from controlled animal experiments and human intervention trials, this chapter aims to clarify the extent to which anthocyanins contribute to cardiovascular disease prevention and management.

5.1 Animal intervention studies

Animal studies have consistently demonstrated the protective effects of anthocyanins against cardiovascular disease through various mechanistic pathways. For instance, research has shown that anthocyanins can significantly reduce oxidative stress and inflammation, two key contributors to vascular dysfunction^[28]. Furthermore, findings indicate that anthocyanins modulate lipid metabolism, improve endothelial function, and reduce blood pressure in rodent models^[16]. These effects are attributed to the ability of anthocyanins to regulate gene expression related to antioxidant defense and inflammatory pathways^[20]. However, while animal models provide robust evidence for the molecular mechanisms underlying anthocyanin activity, species-specific differences in metabolism and absorption may limit the direct applicability of these findings to humans^[16]. Additionally, many studies utilize doses of anthocyanins that exceed typical dietary intake levels, raising questions about the physiological relevance of observed effects^[5].

5.2 Human intervention studies

Human intervention studies further corroborate the cardiovascular benefits of anthocyanins, although the results are more variable compared to animal studies. Epidemiological evidence suggests that habitual consumption of anthocyanin-rich foods, such as berries, is associated with a reduced risk of cardiovascular events, including nonfatal myocardial infarction and ischemic stroke^[2]. Clinical trials have also reported improvements in biomarkers of cardiovascular health, such as endothelial function, lipid profiles, and inflammatory markers, following anthocyanin supplementation^[1]. However, inconsistencies in study design, participant characteristics, and anthocyanin dosages complicate the interpretation of these findings^[3]. Moreover, some studies highlight the challenges of anthocyanin stability and bioavailability, suggesting that the clinical efficacy of these compounds may depend on factors such as food matrix interactions and individual metabolic variability^[5]. While promising, the current body of evidence underscores the need

for larger, well-designed longitudinal studies to establish causal relationships and optimize therapeutic strategies ^[3].

5.3 Gaps and future directions

Despite the growing body of evidence supporting the cardiovascular benefits of anthocyanins, significant gaps remain in understanding their long-term effects and optimal usage. For instance, the stability of anthocyanins under different processing and storage conditions requires further investigation, as highlighted by recent reviews ^[3]. Additionally, the lack of standardized methodologies across studies complicates comparisons and meta-analyses, emphasizing the need for harmonized protocols in future research ^[16]. Addressing these limitations will be crucial for advancing the translation of preclinical findings into effective dietary recommendations and therapeutic interventions ^[11].

6 Conclusion

This comprehensive review highlights the current state of research on the effects of anthocyanins on cardiovascular disease (CVD), emphasizing their potential as dietary interventions for mitigating CVD risks. Anthocyanins, a class of flavonoids widely distributed in nature, have emerged as key bioactive compounds with promising antioxidant, anti-inflammatory, and metabolic regulatory properties. While findings from both preclinical and clinical studies underscore their therapeutic potential, significant gaps in understanding and methodological challenges persist. This chapter synthesizes the main research contributions, identifies limitations, and proposes directions for future investigation to advance the field.

6.1 Main research findings

The primary contributions of this review lie in its consolidation of evidence supporting the role of anthocyanins in promoting cardiovascular health. Studies demonstrate that anthocyanins exert their protective effects through multiple mechanisms, including scavenging reactive oxygen species, modulating lipid metabolism, enhancing insulin sensitivity, and reducing chronic inflammation ^{[18][15]}. These mechanisms are further corroborated by their impact on key biomarkers such as LDL cholesterol, HDL cholesterol, and inflammatory cytokines ^{[21][22]}. Moreover, emerging evidence suggests that anthocyanins influence gene and protein expression via epigenetic modifications and microRNA regulation, offering novel insights into their molecular pathways ^[15]. The integration of findings from natural sources, chemical properties, and experimental studies provides a robust framework for understanding how anthocyanins contribute to vascular function and overall cardiovascular health ^[7]. Collectively, these findings reinforce the importance of anthocyanin-rich diets as a preventive strategy against CVD, while also highlighting their potential as therapeutic agents in chronic disease management.

6.2 Limitations and research gaps

Despite the progress made, several limitations and research gaps hinder the robustness of current knowledge. First, the variability in study designs, dosages, and participant characteristics across human and animal studies complicates the interpretation of results ^[3]. For instance, many animal models utilize doses of anthocyanins that exceed typical dietary intake levels, raising questions about the physiological relevance of observed effects ^[5]. Second, challenges related to anthocyanin stability, bioavailability, and metabolic fate remain unresolved, limiting the ability to predict their clinical efficacy under real-world conditions ^[4]. Third, the lack of standardized methodologies across studies impedes meta-analyses and comparisons, underscoring the need for harmonized protocols ^[16]. Additionally, existing research predominantly focuses on short-term effects, leaving the long-term safety and efficacy of anthocyanin supplementation poorly understood ^[11]. These limitations highlight the need for more rigorous investigations to validate the translational relevance of preclinical findings and ensure the reliability of dietary recommendations.

6.3 Directions for future research

To address these gaps, future research should prioritize several key areas. First, large-scale, longitudinal clinical trials are needed to establish causal relationships between anthocyanin intake and CVD outcomes, particularly in diverse populations with varying genetic and environmental factors ^[3]. Such studies should employ standardized doses and controlled dietary contexts to enhance comparability and reproducibility. Second, advancements in analytical techniques and biomarker discovery are essential for elucidating the metabolic pathways and systemic distribution of anthocyanins ^[7]. Third, investigations into innovative formulations and delivery systems could optimize the stability and bioavailability of anthocyanins, paving the way for more effective nutritional interventions ^[9]. Finally, interdisciplinary collaborations

integrating molecular biology, nutrition science, and public health perspectives are critical for addressing the multifaceted challenges associated with anthocyanin research^[11]. By pursuing these directions, future studies can provide deeper insights into the therapeutic potential of anthocyanins and inform evidence-based strategies for improving cardiovascular health outcomes.

References

- [1] Wallace CT. Anthocyanins and cardiovascular disease prevention[J]. *The FASEB Journal*, 2012, 26(10): 261026.2-1026.2.
- [2] Aedin C, Monica B, Stephanie C, et al. Habitual intake of anthocyanins and flavanones and risk of cardiovascular disease in men. [J]. *The American journal of clinical nutrition*, 2016, 104(3): 587-94.
- [3] Yadav S, Sharma A, Bishnoi S, et al. The Role of Anthocyanins in Cardiovascular Health: A Review. [J]. *Current cardiology reviews*, 2025.
- [4] Pojer E, Mattivi F, Johnson D, et al. The Case for Anthocyanin Consumption to Promote Human Health: A Review [J]. *Comprehensive Reviews in Food Science and Food Safety*, 2013, 12(5): 483-508.
- [5] Eleanor W, Sabine H, Christian H, et al. Blueberries and cardiovascular disease prevention. [J]. *Food & function*, 2019, 10(12): 7621-7633.
- [6] Agri-food CANADA. Anthocyanins and heart health [J]. 2007.
- [7] Antonella S, Davide B, Ersilia B, et al. Chemistry, Pharmacology and Health Benefits of Anthocyanins. [J]. *Phytotherapy research: PTR*, 2016, 30(8): 1265-86.
- [8] Arpita B, Michael R, J T L. Berries: emerging impact on cardiovascular health. [J]. *Nutrition reviews*, 2010, 68(3): 168-77.
- [9] Salsabila EKA, Setia NINGRUM, Ludy WIJI, et al. Formulation and potential of purple cabbage (*Brassica oleracea* L.) as a nutraceutical product in maintaining cardiovascular health [J]. 2023.
- [10] Carvalho F, Lahlou A R, Silva R L. Phenolic Compounds from Cherries and Berries for Chronic Disease Management and Cardiovascular Risk Reduction [J]. *Nutrients*, 2024.
- [11] ZHANG Y. Study on the Dietary Intake of Anthocyanins in Chinese People and Effect of Anthocyanins on Cardiovascular Disease [J]. *Highlights in Science, Engineering and Technology*, 2022, 19: 58-65.
- [12] MOZOS I, FLANGEA C, VLAD D C, et al. Effects of Anthocyanins on Vascular Health [J/OL]. *Biomolecules*, 2021, 11(6): 811 [2025-08-29].
- [13] Maciej D, Agnieszka M, Beata N, et al. The Effects of Natural Iridoids and Anthocyanins on Selected Parameters of Liver and Cardiovascular System Functions. [J]. *Oxidative medicine and cellular longevity*, 2020, 2020: 2735790.
- [14] KOWALCZYK E, et al. Wpływ antocyjanin z aronii czarnoowocowej na angiogenezę u zwierząt otrzymujących kadm [J]. *Farmacja Polska*, 2002, 58(20): 940-9.
- [15] KRGA I, MILENKOVIC D. Anthocyanins: From Sources and Bioavailability to Cardiovascular-Health Benefits and Molecular Mechanisms of Action [J]. *Journal of Agricultural and Food Chemistry*, 2019, 67(7): 1771-1783.
- [16] DE PASCUAL-TERESA S, MORENO D A, GARCÍA-VIGUERA C. Flavanols and Anthocyanins in Cardiovascular Health: A Review of Current Evidence [J/OL]. *International Journal of Molecular Sciences*, 2010, 11(4): 1679-1703 [2025-08-29].
- [17] MATTIOLI R, FRANCIOSIO A, MOSCA L, et al. Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases [J/OL]. *Molecules*, 2020, 25(17): 3809 [2025-08-29].
- [18] FENG Y, QIAO B, LU X, et al. Anthocyanins in Vascular Health and Disease: Mechanisms of Action and Therapeutic Potential [J]. *Journal of Cardiovascular Pharmacology*, 2024, 84(3): 289-302.
- [19] LAJOLO F M, FAGUNDES-NETO U. The role of anthocyanins in health and disease [J]. *Biochemistry (Moscow)*, 2004, 69(2): 153-159.
- [20] AMINI A M. Effects of anthocyanins on the immune and cardiovascular system [D]. Reading: University of Reading, 2017.
- [21] WALLACE T C, SLAVIN M, FRANKENFELD C L. Systematic Review of Anthocyanins and Markers of Cardiovascular Disease [J/OL]. *Nutrients*, 2016, 8(1): 32 [2025-08-29].
- [22] QIN Y, XIA M, MA J, et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects [J]. *The American Journal of Clinical Nutrition*, 2009, 90(3): 485-492.
- [23] TAKIKAWA M, INOUE S, HORIO F, et al. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice [J]. *The Journal of Nutrition*, 2010, 140(3): 527-533.
- [24] QIN Qijie, ZHANG Zhenwen, PENG Xiaoming. Research progress on the preventive and therapeutic effects of proanthocyanidins on cardiovascular diseases [J]. *Xiandai Yiyao Weisheng (Modern Medicine and Health)*, 2021, 37(1): 72-75.
- [25] YANG Xueying, ZHANG Chu, CAO Tingting, et al. Research progress on the mechanism of proanthocyanidins in the treatment of cardiovascular diseases [J]. *Linchuang Junyi Zazhi (Journal of Clinical Military Medicine)*, 2013, 41(11): 1197-1200.
- [26] YOU Bei'an, GAO Haiqing. Cardiovascular protective effects of grape seed proanthocyanidins [J]. *Guowai Yixue Xinxueguan Jibing Fence (Foreign Medical Sciences, Section of Cardiovascular Diseases)*, 2003, (6): 362-363.
- [27] Nima MOHAMMADI, Michelle FARRELL, Laura O'SULLIVAN, et al. Effectiveness of anthocyanin-containing foods and nutraceuticals in mitigating oxidative stress, inflammation, and cardiovascular health-related biomarkers: a systematic review of animal and human interventions. [J]. *Food & function*, 2024.
- [28] LIANG Ying. Research progress on the prevention and treatment of cardiovascular diseases with proanthocyanidins [J]. *Qilu Yaoshi (Qilu Pharmaceutical Affairs)*, 2005, (4): 233-235.